Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Lisa Demoen

Post-doctoral Fellow

research interests

Patients with myeloproliferative neoplasms (MPN) produce too much of a particular blood cell, i.e. red blood cells, platelets or certain white blood cells. Additionally, these patients have an elevated risk to develop a secondary acute myeloid leukaemia (sAML), also known as blast phase MPN (MPN-BP). MPN-BP is an aggressive form of leukaemia with a median survival of less than six months. Therefore, the aim of my research is to identify novel therapeutic strategies and investigate why MPN sometimes transforms into an aggressive leukaemia.

background

I completed my BSc and MSc in Biochemistry and Biotechnology at the University of Antwerp (Belgium). In my masters I became interested in epigenetics, therefore I went on an Erasmus program at the DKFZ in Heidelberg (Germany) to conduct the internship for my master dissertation. During my time there, I explored epigenetic change in the differentiation of adipocytes. After my masters, I completed my PhD in Ghent University (Belgium) in which I researched the role of the KMT2A-complex members in the context of T-cell lymphoblastic leukaemia (T-ALL).